Paper Details

  1. Home
  2. Paper Details

Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort.

Author: DölleMichael, LeitolfHolger, MannsMichael P, SaborowskiMichael, ZenderSteffen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have shown potential in lowering lipid levels to achieve low-density lipoprotein-cholesterol (LDL-C) treatment goals. This study aimed to describe the clinical use of PCSK9 inhibitors and investigate therapy adherence and safety outside clinical trials.
Paper Details　
Original Abstract of the Article :
Proprotein convertase subtilisin/kexin type 9 (PCSK9)-inhibitors have shown great po-tential in efficient lipid lowering to achieve low-density lipoprotein-cholesterol (LDL-C) treatment goals. The aim of the study was too describe the clinical use of PCSK9-inhibitors and to investigate therapy adher...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.5603/CJ.a2017.0137

データ提供：米国国立医学図書館（NLM）

PCSK9 Inhibitors: A Promising Oasis in the Desert of Cardiovascular Disease

This study examines the real-world use of PCSK9 inhibitors in managing cardiovascular high-risk patients. It's like exploring a desert landscape, where understanding the unique challenges of cardiovascular disease and the potential solutions offered by new medications is crucial for improving patient outcomes. The study explores the effectiveness, adherence, and safety of these drugs in a real-world setting.

PCSK9 Inhibitors: A New Weapon in the Desert

The study highlights the potential of PCSK9 inhibitors in achieving low-density lipoprotein-cholesterol (LDL-C) treatment goals. It's like discovering a new weapon in the desert, capable of effectively combating a formidable enemy. The study emphasizes the need for further research to optimize the use of these drugs in real-world settings.

Navigating Cardiovascular Risk with PCSK9 Inhibitors

This research offers valuable insights into the potential benefits of PCSK9 inhibitors in managing cardiovascular risk. It's like having a new tool to help you navigate the challenging landscape of this disease. The study underscores the importance of personalized approaches, considering individual factors and treatment goals.

Dr.Camel's Conclusion

This study provides a glimpse into the promising future of PCSK9 inhibitors in managing cardiovascular risk. It's like discovering a hidden oasis in the vast desert of cardiovascular disease, offering potential solutions for improving patient outcomes and promoting overall health.

Date :
  1. Date Completed 2018-11-19
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

29168543

DOI: Digital Object Identifier

10.5603/CJ.a2017.0137

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.